Post-Treatment Weight Rebound in Patients Using Anti-Obesity Medications
A new meta-analysis reveals that weight loss achieved through anti-obesity medications often diminishes within weeks after stopping treatment, highlighting the need for sustained weight management strategies.
Recent research indicates that individuals prescribed anti-obesity medications may experience significant weight regain after discontinuing their treatment. A comprehensive meta-analysis, published in BMC Medicine, analyzed data from 11 international studies involving 1,574 participants on medication and 893 control subjects. The findings reveal that while these medications effectively promote weight loss during use, the effects diminish—often sharply—within weeks after cessation.
The study categorized the medications into several types, including GLP-1 receptor agonists (such as semaglutide), dual GLP-1 and dual receptor agonists, orlistat, phentermine-topiramate, and naltrexone-bupropion. The analysis controlled for various factors such as the presence of diabetes and lifestyle changes like diet and exercise.
Results showed that weight loss peaks during treatment but begins to reverse approximately eight weeks after stopping medication. Weight regain continues over an average of 20 weeks before reaching a plateau. The extent of weight regain varies depending on several factors, including the specific medication used and adherence to lifestyle modifications. For instance, individuals who completed a 36-week tirzepatide regimen regained nearly half of the weight lost after switching to a placebo.
The researchers highlight that these findings do not compare medication effects with lifestyle interventions or surgical options like bariatric surgery. Nonetheless, the evidence underscores the challenge of maintaining weight loss after pharmacological treatment ends. The study emphasizes ongoing weight management strategies and regulatory considerations for long-term treatment plans.
In conclusion, anti-obesity drugs are effective for short-term weight reduction, but many patients tend to experience weight rebound after stopping treatment. This underscores the importance of continued support and the potential need for adjunct therapies or lifestyle modifications to sustain weight loss over time.
Source: https://medicalxpress.com/news/2025-07-anti-obesity-medications-weight-rebound.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights Into CDK12 Gene Inactivation as a Key Driver of Aggressive Ovarian Cancer
New research highlights the critical role of CDK12 gene inactivation in driving aggressive ovarian cancer, paving the way for innovative targeted therapies and improved outcomes.
New Research Highlights Motor Coordination Challenges Affecting Imitation and Learning in Children with Autism
A recent large-scale study reveals that impaired motor coordination is a key factor influencing imitation and learning difficulties in children with autism, highlighting the importance of early motor skills intervention.
The Impact of Relative Performance Feedback on Physician Motivation
Effective performance feedback through tailored ranking systems can boost physician motivation and improve healthcare quality. Learn how thoughtful design influences outcomes.
Excess Body Fat and Liver Cancer Immunotherapy Resistance: The Role of Diet in Improved Outcomes
Recent studies reveal that excess body fat within liver tumors can hinder immunotherapy effectiveness. Research suggests that healthier diets and lifestyle choices may improve treatment responses in liver cancer patients resistant to current therapies.